Sarah M Turpin-Nolan 4th Metabolic Diseases; Breakthrough Discoveries in Diabetes & Obesity Meeting 2024

Sarah M Turpin-Nolan

Dr. Sarah Turpin-Nolan is a Senior Research Fellow directing the in the Cellular and Molecular Metabolism Laboratory at the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University, Australia. Sarah completed her PhD (The University of Melbourne (Dept of Medicine & Health Sciences)) and investigated the Metabolic consequences of lipid-oversupply in key glucoregulatory tissues. During her postdoctoral training in Cologne, Germany, Sarah was awarded an Alexander von Humboldt Fellowship and discovered that the reduction of C16:0 ceramide in the liver could prevent diet-induced obesity and type 2 diabetes mellitus, whilst reducing C18:0 ceramide in skeletal muscle improved whole body glucose metabolism. During 2023, Sarah was awarded a REDI Fellowship to work within CSL’s Cardiovascular and Metabolism Therapeutic Area to better understand how basic research can be performed to shorten the development of new therapeutics from “bench to bedside”. Sarah's current research program now focuses upon the role of ceramides during metabolic disease, namely in the gastrointestinal tract, lymphatic, and circulatory transport systems and has been funded by Diabetes Australia, ANSTO and Monash University grants.

Abstracts this author is presenting: